SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Report abuse about a comment

Sponsors involved as well

One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.

Posted by Guillaume Miara
30 August 2011 | 15h30

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Over 50% of sales at top CROs now made outside US; report

Spotlight

'On Immunity': enter BioPharma-Reporter.com’s free book giveaway
Competition

'On Immunity': enter BioPharma-Reporter.com’s free book giveaway

Did you know that throughout the nineteenth century, vaccination left a scar known as “the mark of...

Charles River considers re-opening preclinical site in Mass.

Charles River considers re-opening preclinical site in Massachusetts

CRO Charles River Laboratories (CRL) may re-open a preclinical site in Shrewsbury, MA, if demand for the...

Parexel strong book-to-bill 'reassuring' for CRO demand, says analyst

Parexel strong book-to-bill 'reassuring' for CRO demand, says analyst

Parexel’s improved book-to-bill ratio is a reassuring sign for the company and the CRO industry as a whole,...

Crown expands Precos site to build caucasian cancer expertise

Crown expands Precos site to build caucasian cancer expertise

Crown Biosciences has announced plans to double capacity at a site operated by its Precos division.

Oil slump good for API makers, until a major supplier turns off the tap says industry group

Oil slump good for API makers, until a major supplier turns off the tap says industry group

Falling oil prices are good news for firms that make pharmaceutical ingredients according to a European chemical...

Japan to be hot destination for trials in 2015 say experts, despite drop in MRCTs last year

Japan to be hot destination for trials in 2015 say experts, despite drop in MRCTs last year

Japan was involved in fewer drug industry-sponsored multi-regional clinical trials (MRCT) in 2014 than any year since...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...